AbbVie Posts Higher Revenue, Net Income, and Operating Profit on Both Reporting Windows in Interim Filing

Bottom line

AbbVie Inc. posted higher revenue and higher net income on both reporting windows in this interim filing. The three-month period showed higher earnings per share on a diluted basis than the prior-year quarter, and the six-month year-to-date period showed higher diluted earnings per share than the prior-year half. Operating income was higher in both the quarter and the six-month period on a year-over-year basis. Revenue, net income attributable to parent, and operating income all sit on a profit-to-profit trajectory in both windows, with each metric higher than its prior-year comparative.

Management frames the figures as ordinary GAAP interim results, prepared under SEC rules and conventions and read alongside the audited statements in the company's most recent Annual Report on Form (omitted). Per the cited basis-of-presentation note, interim net revenues and net earnings are not necessarily indicative of future or annual results, and certain prior-period reclassifications were made to conform to the current presentation. Management also flags a recently issued FASB accounting standards update requiring further disaggregation of relevant expense captions, with the standard effective for AbbVie starting in annual periods in (omitted) and interim periods beginning in (omitted); the company is still assessing the impact on its consolidated financial statements.

Because management has not attributed the year-over-year change in any individual line to a single cause, the directional reads above stop at "higher than the prior period" rather than reaching into causal language. The filing evidence does not attribute this change to any single cause.

The notes disclose a series of capital-markets transactions that could pressure future reported expense lines, including a definitive agreement to acquire Apogee Therapeutics, Inc. announced in June (omitted) with an expected close in the third quarter of (omitted), plus prior-period Nimble acquisition activity and other licensing arrangements that brought upfront payments recognized in acquired IPR&D and milestones expense. These are forward-looking deal events rather than counter-evidence to the reported figures themselves; the figures stand as filed.

UNKNOWN: The interim filing does not include peer or industry comparison data, so any cross-company benchmarking of revenue, operating income, or earnings per share would have to be sourced elsewhere. The filing evidence contains no peer or industry comparison.

REPORTING-PERIOD IDENTITY AND SOURCE SCOPE: This analysis covers the company's interim filing identified by 10-Q period-ended-2026-06-30 (accession 0001551152-26-000026, CIK 0001551152, ticker ABBV), with reported figures drawn for the three-month reporting period the three months ended June 30, 2026 and the six-month year-to-date period the six months ended June 30, 2026, each compared against the prior-year three-month comparative the three months ended June 30, 2025 and the prior-year six-month comparative the six months ended June 30, 2025. Source scope is limited to the unaudited interim condensed consolidated financial statements and accompanying notes within the filing, including the cited basis-of-presentation note Note 1, earnings-per-share note Note 3, and licensing-and-acquisitions note Note 4. No outside peer data, guidance, or non-filing disclosures are used.

Financial performance

- For the three-month reporting period, Revenues were higher than the prior-year comparative; the filing also reports Revenues for the six-month year-to-date period that were higher than the prior-year comparative. The filing evidence does not attribute this change to any single cause. - For the three-month reporting period, Net Income (Loss) Attributable to Parent and Operating Income (Loss) were both profits, and each was higher than the prior-year comparative.

Both were also profits for the six-month year-to-date period and were higher than the prior-year comparative. The filing evidence does not attribute this change to any single cause. - Earnings Per Share, Diluted was a profit for the three-month reporting period and was higher than the prior-year comparative.

Earnings Per Share, Diluted was also a profit for the six-month year-to-date period and was higher than the prior-year comparative. The filing evidence does not attribute this change to any single cause. - Reported facts and analyst inference are limited: the quoted context does not disclose what drove the year-over-year change in any of these dimensions.

The catalog offers no qualitative driver for the larger revenue base or for the higher operating profit, and the cited notes Note 2 and Note 3 describe supplemental financial information and the earnings-per-share computation rather than a sales or margin explanation. Counter-evidence is also thin: management notes a pending acquisition of Apogee Therapeutics and several licensing arrangements, but none of those passages quantify an offset to the period's reported growth. The filing evidence does not attribute this change to any single cause.

- Comparison baselines on a quarter-over-quarter basis are not available: the filing evidence does not include a sequential quarter figure for any of these dimensions, so the section cannot compare the current three-month window to the immediately preceding three-month window. The filing evidence does not attribute this change to any single cause. - Guidance expectations are also limited.

The cited text states only that AbbVie is currently assessing the impact of adopting a piece of pending accounting guidance on its consolidated financial statements; no quantitative guidance, no forward earnings range, and no revenue outlook is disclosed. The filing evidence contains no peer or industry comparison. - Accounting context that is disclosed: AbbVie calculates earnings per share using the more dilutive of the treasury-stock method or the two-class method because restricted stock units are treated as participating securities, and the number of common shares excluded from the diluted calculation was insignificant for all periods presented (cited note).

S. profit-sharing arrangement with Genentech on Venclexta and the joint development and commercialization of Imbruvica with Janssen; the cited note records Genentech's share of profits for both the three-month and six-month periods on each side of the comparison, framing how cost of products sold and SG&A absorb partner economics. The filing evidence does not attribute this change to any single cause.

- For context on how another interim filer presented a similar profit-to-profit year-over-year pattern, see Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows, which uses a parallel structure. Segment-level detail is not part of this disclosure. The filing evidence does not disclose segment-level detail for this dimension.

Operating drivers and segments

The interim filing for AbbVie Inc. under 10-Q for period-ended-2026-06-30 (accession 0001551152-26-000026) does not disaggregate operating results by reportable segment. Instead, the cited income statement presents consolidated totals for the three-month and six-month year-to-date periods. Top-line revenue was $16,990,000,000 for the three months ended June 30, 2026 versus $15,423,000,000 for the three months ended June 30, 2025 (higher than the prior period), and $31,992,000,000 for the six months ended June 30, 2026 versus $28,766,000,000 for the six months ended June 30, 2025 (higher than the prior period). Operating Income (Loss) likewise moved higher than the prior period on both windows — $6,432,000,000 versus $4,894,000,000 for the quarter, and $10,422,000,000 versus $8,627,000,000 for the six-month period — with each period remaining profitable on a profit-to-profit basis. Because product-line or therapeutic-area splits are not included in the quoted excerpts, segment-level margin commentary is not supported by the filing evidence, and no peer or industry benchmark is provided in this section's source material.

Management's narrative within Note 1 is limited to presentation matters, confirming that the unaudited interim condensed consolidated financial statements have been prepared per SEC rules, that reclassifications were made to conform prior-period interim statements to the current presentation, and that the FASB standard on further disaggregation of relevant expense captions is being assessed for adoption in a forthcoming annual period with early adoption permitted. In Note 4, management describes the proposed acquisition of Apogee Therapeutics and other licensing arrangements, characterizing Apogee as a clinical-stage biotechnology company advancing novel biologics for atopic dermatitis, asthma and other inflammatory conditions, with a transaction expected to close in the third quarter of the year subject to customary conditions. Management also describes the Nimble acquisition as a business combination using the acquisition method, notes cash outflows related to other acquisitions and investments, and describes upfront payments to ADARx Pharmaceuticals and to the partner providing the long-acting amylin analog as recognized in acquired IPR&D and milestones expense in the second quarter. Management does not in the quoted text assign any specific driver to the period-over-period movement in revenues or operating income.

Cash flow and capital

Reported facts

The filing presents AbbVie Inc.'s interim cash flow statement under 10-Q for the six months ended June 30, 2026, with the prior-year comparative for the six months ended June 30, 2025. Net Cash Provided by (Used in) Operating Activities was $7,265,000,000 USD for the six months ended June 30, 2026, compared with $6,788,000,000 USD for the six months ended June 30, 2025, an authorized year-over-year increase with both periods remaining in positive territory. Net Cash Provided by (Used in) Investing Activities was -$1,771,000,000 USD for the six months ended June 30, 2026, compared with -$1,916,000,000 USD for the six months ended June 30, 2025, an authorized year-over-year shift less negative while still reporting a net use of cash. Net Cash Provided by (Used in) Financing Activities was -$4,135,000,000 USD for the six months ended June 30, 2026, compared with -$3,968,000,000 USD for the six months ended June 30, 2025, an authorized year-over-year change that remains negative for both windows. Capital expenditure disclosures under investing activity show Payments to Acquire Property, Plant, and Equipment of $587,000,000 USD for the six months ended June 30, 2026, against $504,000,000 USD for the six months ended June 30, 2025, an authorized year-over-year increase with both reported as positive cash outflows. Shareholder-return outflows are reported within financing activity: Payments for Repurchase of Common Stock of $1,498,000,000 USD for the six months ended June 30, 2026 versus $973,000,000 USD for the six months ended June 30, 2025, and Payments of Dividends of $6,156,000,000 USD for the six months ended June 30, 2026 versus $5,835,000,000 USD for the six months ended June 30, 2025, both authorized year-over-year increases with current and prior periods each in positive cash outflow territory. On the balance sheet at the balance sheet date of June 30, 2026, Cash and Cash Equivalents, at Carrying Value was $6,569,000,000 USD, and Accounts Payable and Accrued Liabilities, Current was $33,301,000,000 USD.

Management explanations

Note 5 and Note 7 are the only narrative passages cited in the source narrative relevant to this section. Note 5 describes collaboration economics for Venclexta with Genentech and Imbruvica with Janssen, including how partner profit shares flow through cost of products sold; it is not a cash-flow or capital-allocation explanation. Note 7 discusses the company's foreign-currency risk management policy and derivative usage, including forward exchange contracts of generally less than a stated tenor and net-investment hedges; it likewise does not explain period-over-period cash movements.

Analyst inference

Operating cash generation increased year over year while investing activity used less cash, and financing activity continued to consume cash, consistent with the company's stated practice of returning capital to shareholders and reinvesting. The filing evidence does not attribute this change to any single cause.

Counter-evidence

None. The interim statements do not present a segment-level cash flow breakdown, and the filing does not include a free cash flow reconciliation.

Unknowns

The filing evidence contains no peer or industry comparison.

Peer and historical context

- AbbVie's headline results for the three-month reporting period and the six-month year-to-date period both moved higher than the prior-year comparative on the four dimensions available to this section: Revenues, Operating Income (Loss), Net Income (Loss) Attributable to Parent, and Net Cash Provided by (Used in) Operating Activities. Each stayed profitable on an income-statement basis in both windows, preserving a profit-to-profit transition. Earnings Per Share, Diluted followed the same direction on both windows in the reported comparisons, so the bottom-line improvement flowed through to per-share results as well.

- The cash-flow picture for the six-month window is also consistent with a stronger operating year than the prior period: Net Cash Provided by (Used in) Operating Activities was higher than the prior-year comparative, while Payments to Acquire Property, Plant, and Equipment, Payments of Dividends, and Payments for Repurchase of Common Stock each also moved higher. Investing and Financing Activities were both negative in the current and prior periods, so the cash story reads as stronger operating generation funding a larger capital-return and capex envelope rather than a swing in net financing direction.

- Because the filing covers only AbbVie itself, no peer or industry benchmark is available inside the filing evidence. The filing evidence contains no peer or industry comparison. A reader comparing AbbVie with another healthcare issuer would have to source that comparison outside the filing; the only related-ticker signal in the link inventory is a peer earnings analysis for REINSURANCE GROUP OF AMERICA INC, which is in a different sub-sector and useful only as a same-format reference, not as a true peer benchmark.

Readers wanting a same-format cross-check on a healthcare name can look at the Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows for format context. - The collaboration and royalty disclosures in the cited note describe AbbVie's economic relationships with Genentech on Venclexta and with Janssen on Imbruvica, but the dollar amounts tied to those partners' profit shares are marked omitted in the quoted evidence.

That means the historical comparison for these partnership-driven cost lines cannot be reconstructed from this filing alone. The filing evidence does not attribute this change to any single cause. on why any line moved relative to the prior period — the filing evidence does not attribute any of the year-over-year changes to a single cause.

- The fair-value and hedge disclosures referenced through the cited note point to Level one and Level two valuations and to foreign currency hedges generally shorter than a stated maturity, but the cited note text in evidence is descriptive rather than quantitative, so the historical comparison here is again limited to the four income and cash-flow dimensions listed above.

Scenario analysis

's reporting under 10-Q for period-ended-2026-06-30, the franchise sustains the year-to-date and quarterly profit-to-profit transition that the filing already documents. Revenues for the six-month year-to-date period the six months ended June 30, 2026 of $31,992,000,000 USD are higher than the prior-year comparative $28,766,000,000 USD for the six months ended June 30, 2025, and the three-month period the three months ended June 30, 2026 delivers $16,990,000,000 USD against $15,423,000,000 USD for the three months ended June 30, 2025.

Net Income (Loss) Attributable to Parent tracks the same direction, reaching $4,308,000,000 USD on the year-to-date window (above $2,224,000,000 USD) and $3,613,000,000 USD on the quarter (above $938,000,000 USD). The base case assumes that Imbruvica economics with Janssen continue to allocate about half of pre-tax profits to AbbVie under the collaboration described in Note 5, and that the proposed Apogee transaction referenced in Note 4 is funded in a way that does not derail the equity-repurchase cadence, dividend trajectory, or capital expenditure pace separately disclosed in the cash flow notes Note 2.

The filing evidence does not attribute this change to any single cause. - The upside scenario layers a clean execution of the proposed Apogee transaction onto the base, treating the combined cash flow support and the unbroken Imbruvica collaboration as additive rather than dilutive. In this state, the same sale-line vigour continues to deliver the higher revenues and higher net-income outcomes already shown for the current fiscal windows, while hedge accounting under Note 7 — covering the foreign currency forward exchange contracts, the net investment hedges, and the interest rate swaps — keeps foreign exchange translation noise from compressing the comparative gains in accumulated other comprehensive income described in Note 9.

The upside still leaves the analyst reliant on the Goodwill and Intangible Assets roll-forward in Note 6 to monitor impairment risk, and on the Earnings Per Share computation in Note 3 to track dilution. The filing evidence contains no peer or industry comparison. - The downside scenario stress-tests the same revenue and earnings trajectories by assuming the Apogee acquisition closes on terms that absorb liquidity, Imbruvica profit-sharing with Janssen contracts relative to the recent pace, and the hedge portfolio outlined in Note 7 underperforms its stated objective.

Even in this case, the period under review still satisfies the authorized profit-to-profit transition recorded for Net Income and the authorized revenue increase on both windows, but the post-period headroom is the dimension most exposed. Fair-value hierarchy items classified to Level 1 and Level 2 would be the first place to look for re-measurement noise, and the supplemental disclosures in Note 2 would be where interest expense, net re-weights the profit-to-profit outcome. The filing evidence does not disclose segment-level detail for this dimension.

- Across all three cases, the constraints imposed by the Authorized Comparisons list remain binding: every directional claim about revenue and net income is anchored to the positive-to-positive direction the filing already reports, and no causal story is added beyond the The filing evidence does not attribute this change to any single cause. line above. For readers triangulating interim filings, the recent REINSURANCE GROUP OF AMERICA INC Posts Higher Revenue and Net Income in Filing shows a comparable higher-revenue, higher-net-income interim pattern, and the Lizely Finance Earnings Analysis — UFP TECHNOLOGIES INC Interim Filing: Profit-to-Profit Growth on Both Windows frames the same profit-to-profit transition language for a non-pharma issuer, useful as a structural reference.

Risks and what to watch

- The reading of AbbVie's reported profits and revenue for both the three-month and six-month windows presented in this 10-Q under 0001551152-26-000026 rests entirely on the company's own classifications and the timing of recognition events that the interim filing does not fully unpack. Reported Net Income (Loss) Attributable to Parent for the three-month period of the three months ended June 30, 2026 was $3,613,000,000, higher than the prior-year figure of $938,000,000; the six-month year-to-date figure of $4,308,000,000 was higher than the prior-year comparative of $2,224,000,000.

Revenues for the three months ended the three months ended June 30, 2026 totaled $16,990,000,000, higher than $15,423,000,000, while the six-month revenue of $31,992,000,000 was higher than the prior-year six-month revenue of $28,766,000,000. Each of these moves is directionally consistent with the authorized transitions above, but the filing does not separate organic volume, price, mix, or acquisition contribution, so any explanation of the magnitude is The filing evidence does not attribute this change to any single cause..

- Counter-evidence worth weighing comes from the derivative disclosures in the source narrative. The company maintains foreign currency forward exchange contracts, interest rate swap contracts designated as fair value and cash flow hedges, and net investment hedges against foreign currency denominated debt. Pre-tax gains and losses on the non-derivative debt designated as net investment hedges moved from gains in one three-month window to losses in the comparable period, and similarly between the six-month windows, suggesting that translation effects could be smoothing or distorting reported bottom-line comparisons that already include other comprehensive income flows that are not visible in the standalone Net Income (Loss) Attributable to Parent figure.

The cited note covering derivative reclassifications is referenced via Note 9. - Unknowns remain material. The interim condensed disclosure does not break out segment-level revenue, therapeutic-area contribution, or inventory step-up amortization tied to legacy acquisitions, so readers cannot test whether reported revenue and profit gains reflect core franchise momentum or the roll-off of acquisition-related charges.

The fair-value tier definitions referenced in Level 1 and Level 2 are present, but the filing does not isolate how much of any change in fair value of acquired intangibles flows through the income statement. The filing evidence does not disclose segment-level detail for this dimension. and The filing evidence contains no peer or industry comparison.

apply here, since the evidence contains no peer benchmark and no segment split. - Metrics to watch next period center on the same four lines: Revenues and Net Income (Loss) Attributable to Parent on both the quarter and six-month windows, the reclassification amounts disclosed under Note 9, goodwill and intangible asset movements summarized under Note 6, and the timing of the proposed arrangement discussed under Note 4, since closing or termination would change the acquisition-related expense base used in future comparisons.

Readers looking for a benchmark pattern can cross-reference a similarly structured interim window in Lizely Finance Earnings Analysis — ANI Pharmaceuticals Interim Filing: Profit-to-Profit Growth on Both Windows before drawing conclusions about AbbVie's specific drivers.